questionsmedicales.fr
Phénomènes génétiques
Structures génétiques
Génome
Composants de génome
Gènes
Gènes régulateurs
Gènes switch
Gènes switch : Questions médicales fréquentes
Termes MeSH sélectionnés :
Programmed Cell Death 1 Receptor
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Gènes switch : Questions médicales les plus fréquentes",
"headline": "Gènes switch : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Gènes switch : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-19",
"dateModified": "2025-03-14",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Gènes switch"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Gènes régulateurs",
"url": "https://questionsmedicales.fr/mesh/D005809",
"about": {
"@type": "MedicalCondition",
"name": "Gènes régulateurs",
"code": {
"@type": "MedicalCode",
"code": "D005809",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G05.360.340.024.340.425"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Gènes switch",
"alternateName": "Genes, Switch",
"code": {
"@type": "MedicalCode",
"code": "D005812",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Martin Fussenegger",
"url": "https://questionsmedicales.fr/author/Martin%20Fussenegger",
"affiliation": {
"@type": "Organization",
"name": "ETH Zürich, Department of Biosystems Science and Engineering, Mattenstrasse 26, 4058, Basel, Switzerland; University of Basel, Faculty of Life Science, Basel, Switzerland. Electronic address: fussenegger@bsse.ethz.ch."
}
},
{
"@type": "Person",
"name": "Ana Palma Teixeira",
"url": "https://questionsmedicales.fr/author/Ana%20Palma%20Teixeira",
"affiliation": {
"@type": "Organization",
"name": "ETH Zürich, Department of Biosystems Science and Engineering, Mattenstrasse 26, 4058, Basel, Switzerland."
}
},
{
"@type": "Person",
"name": "Jin Wang",
"url": "https://questionsmedicales.fr/author/Jin%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Physics and Applied Mathematics, State University of New York at Stony Brook, Stony Brook, New York 11794, USA."
}
},
{
"@type": "Person",
"name": "Jörg S Hartig",
"url": "https://questionsmedicales.fr/author/J%C3%B6rg%20S%20Hartig",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Konstanz, Universitätsstraße 10, 78457 Konstanz, Germany; Konstanz Research School Chemical Biology (KoRS-CB), University of Konstanz, Universitätsstraße 10, 78457 Konstanz, Germany. Electronic address: joerg.hartig@uni-konstanz.de."
}
},
{
"@type": "Person",
"name": "Omer Gokcumen",
"url": "https://questionsmedicales.fr/author/Omer%20Gokcumen",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.",
"datePublished": "2023-09-09",
"url": "https://questionsmedicales.fr/article/37862797",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejca.2023.113337"
}
},
{
"@type": "ScholarlyArticle",
"name": "Lichen Planopilaris Pemphigoides: A Novel Bullous Dermatosis Due to Programmed Cell Death Protein-1 Inhibitor Therapy.",
"datePublished": "2023-02-20",
"url": "https://questionsmedicales.fr/article/36825932",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/DAD.0000000000002392"
}
},
{
"@type": "ScholarlyArticle",
"name": "Programmed Death 1 (PD-1) Expression in Relapsing and Remitting Hodgkin Lymphoma as Prognostic Factor.",
"datePublished": "2023-08-01",
"url": "https://questionsmedicales.fr/article/37642071",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.31557/APJCP.2023.24.8.2829"
}
},
{
"@type": "ScholarlyArticle",
"name": "Analysis of Programmed Cell Death-1 (PD-1) Gene Variations (re11568821 and rs41386349) in HTLV-1 Infection Using One Primer Pair and Proviral Load.",
"datePublished": "2023-04-05",
"url": "https://questionsmedicales.fr/article/37020064",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00239-023-10104-5"
}
},
{
"@type": "ScholarlyArticle",
"name": "Programmed cell death protein 1 axis blockade in locally advanced squamous cell carcinoma of the head and neck: Neoadjuvant and adjuvant approaches.",
"datePublished": "2022-07-16",
"url": "https://questionsmedicales.fr/article/35868194",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ctrv.2022.102437"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes génétiques",
"item": "https://questionsmedicales.fr/mesh/D055614"
},
{
"@type": "ListItem",
"position": 3,
"name": "Structures génétiques",
"item": "https://questionsmedicales.fr/mesh/D040342"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génome",
"item": "https://questionsmedicales.fr/mesh/D016678"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composants de génome",
"item": "https://questionsmedicales.fr/mesh/D040481"
},
{
"@type": "ListItem",
"position": 6,
"name": "Gènes",
"item": "https://questionsmedicales.fr/mesh/D005796"
},
{
"@type": "ListItem",
"position": 7,
"name": "Gènes régulateurs",
"item": "https://questionsmedicales.fr/mesh/D005809"
},
{
"@type": "ListItem",
"position": 8,
"name": "Gènes switch",
"item": "https://questionsmedicales.fr/mesh/D005812"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Gènes switch - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Gènes switch",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Gènes switch",
"description": "Comment identifier un gène switch ?\nQuels tests sont utilisés pour les gènes switch ?\nLes gènes switch sont-ils visibles sur une analyse génétique ?\nPeut-on détecter des mutations dans les gènes switch ?\nQuels marqueurs sont associés aux gènes switch ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=5#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Gènes switch",
"description": "Quels symptômes sont liés aux gènes switch ?\nLes gènes switch affectent-ils le développement ?\nPeut-on observer des anomalies dues aux gènes switch ?\nLes gènes switch influencent-ils le comportement ?\nY a-t-il des symptômes neurologiques associés ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=5#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Gènes switch",
"description": "Peut-on prévenir les maladies liées aux gènes switch ?\nQuels modes de vie peuvent aider à prévenir ces maladies ?\nLes conseils génétiques sont-ils utiles ?\nY a-t-il des vaccins pour prévenir les effets des gènes switch ?\nComment le suivi médical contribue-t-il à la prévention ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=5#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Gènes switch",
"description": "Comment traiter les dysfonctionnements des gènes switch ?\nLes traitements sont-ils personnalisés ?\nY a-t-il des essais cliniques pour ces traitements ?\nLes traitements sont-ils efficaces ?\nQuels effets secondaires peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=5#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Gènes switch",
"description": "Quelles complications peuvent survenir avec les gènes switch ?\nLes gènes switch peuvent-ils causer des maladies héréditaires ?\nY a-t-il des risques de transmission familiale ?\nLes complications sont-elles réversibles ?\nComment les gènes switch affectent-ils la longévité ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=5#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Gènes switch",
"description": "Quels facteurs de risque sont associés aux gènes switch ?\nL'âge est-il un facteur de risque ?\nLe mode de vie influence-t-il les gènes switch ?\nLes facteurs génétiques jouent-ils un rôle ?\nLes infections peuvent-elles affecter les gènes switch ?",
"url": "https://questionsmedicales.fr/mesh/D005812?mesh_terms=Programmed+Cell+Death+1+Receptor&page=5#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment identifier un gène switch ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'identification se fait par des techniques comme le séquençage et l'analyse d'expression génique."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour les gènes switch ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de PCR et des analyses de microarray sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Les gènes switch sont-ils visibles sur une analyse génétique ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent être détectés indirectement par l'expression des gènes qu'ils régulent."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des mutations dans les gènes switch ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations peuvent être identifiées par séquençage ciblé."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés aux gènes switch ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs épigénétiques comme les méthylations peuvent indiquer leur activité."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés aux gènes switch ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient selon les gènes régulés, incluant des troubles métaboliques."
}
},
{
"@type": "Question",
"name": "Les gènes switch affectent-ils le développement ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils jouent un rôle crucial dans le développement embryonnaire et cellulaire."
}
},
{
"@type": "Question",
"name": "Peut-on observer des anomalies dues aux gènes switch ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies peuvent se manifester par des malformations congénitales ou des cancers."
}
},
{
"@type": "Question",
"name": "Les gènes switch influencent-ils le comportement ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains gènes switch peuvent affecter des traits comportementaux et cognitifs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes neurologiques associés ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines dysrégulations peuvent entraîner des troubles neurologiques variés."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les maladies liées aux gènes switch ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par le dépistage génétique et des interventions précoces."
}
},
{
"@type": "Question",
"name": "Quels modes de vie peuvent aider à prévenir ces maladies ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, est bénéfique."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques aident à évaluer les risques et à planifier des actions préventives."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins pour prévenir les effets des gènes switch ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiques pour les gènes switch."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical contribue-t-il à la prévention ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet de détecter précocement des anomalies et d'intervenir rapidement."
}
},
{
"@type": "Question",
"name": "Comment traiter les dysfonctionnements des gènes switch ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies géniques et des médicaments ciblés peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction du profil génétique du patient."
}
},
{
"@type": "Question",
"name": "Y a-t-il des essais cliniques pour ces traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, de nombreux essais cliniques explorent des thérapies pour les gènes switch."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité varie selon le type de gène switch et la pathologie associée."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires peuvent inclure des réactions immunitaires ou des complications."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec les gènes switch ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des cancers, des troubles métaboliques et des malformations."
}
},
{
"@type": "Question",
"name": "Les gènes switch peuvent-ils causer des maladies héréditaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains gènes switch sont impliqués dans des maladies héréditaires complexes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de transmission familiale ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les gènes switch peuvent être transmis et affecter plusieurs membres d'une famille."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être irréversibles."
}
},
{
"@type": "Question",
"name": "Comment les gènes switch affectent-ils la longévité ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dysfonctionnements peuvent réduire l'espérance de vie en augmentant le risque de maladies."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux gènes switch ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des facteurs environnementaux, génétiques et comportementaux peuvent influencer leur activité."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'âge peut affecter l'expression des gènes switch et le risque de maladies."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il les gènes switch ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le tabagisme ou l'alimentation peuvent moduler leur activité."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des variations génétiques peuvent prédisposer à des dysfonctionnements des gènes switch."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles affecter les gènes switch ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections peuvent altérer l'expression des gènes switch et provoquer des maladies."
}
}
]
}
]
}
Epstein-Barr virus-associated intrahepatic cholangiocarcinoma (EBVaICC) has a distinct genomic profile and increased CD3...
Patients with metastatic biliary tract cancer (BTC) diagnosed at Sun Yat-sen University Cancer Center from January 2016 to December 2021 were identified. In situ hybridisation was performed to detect ...
A total of 698 patients with metastatic BTC were identified, of whom 39 (5.6%) had EBVaICC. Among the 136 patients who were not administered PD-1 antibody, the OS was similar between patients with EBV...
This study identified a clinically actionable subset of patients with EBVaICC with a promising response to the PD-1 antibody....
Lichen planus pemphigoides (LPPemph), apart from bullous pemphigoid, is a rare bullous dermatosis that can be induced by programmed cell death protein-1 (PD-1)/PD ligand 1 (PD-L1) inhibitors. The prim...
Programmed death ligand 1 (PD-L1) plays critical role in PD-1-dependent immunity suppress. Abnormal PD-L1 expression has shown to be directly related to poor prognosis and drug resistance in cancer pa...
In this cross-sectional study, 100 patients with HL between 2007 and 2015, were included. A thin section of tumor tissue fixed and processed on slides, stained by immunohistochemistry (IHC) PD-L1 spec...
of 100 HL cases, the mean age of 33 relapsed group cases was significantly higher than remission group (p-value = 0.006), and gender was not significant however majority of cases in both groups were m...
PD-L1 expression assessment in HL patients is a valuable tool for prediction of the disease subtype, progression, stage, and treatment outcome. IHC method as an available, simple, rather cheap, and ef...
About 90% of people infected with Human T lymphotropic virus type-1 (HTLV-1) virus are asymptomatic, so it can be said that the prevalence of this virus is not completely clear. During chronic infecti...
Immunotherapy and in particular programmed cell death protein 1 (PD-1) inhibitors have been applied not only in the management of recurrent or metastatic disease but also as component of potentially c...
Programmed cell death-1 (PD-1) inhibitor was proven to be useful for the recurrent/metastatic head and neck squamous carcinoma (R/M HNSCC) patients. Though both PD-1 inhibitor alone and combination wi...
We consecutively enrolled the R/M HNSCC patients treated with concurrent PD-1 inhibitor and chemoradiotherapy from August 2018 to April 2022 in Sichuan Cancer hospital. All the patients received the c...
40 R/M HNSCC patients were enrolled in our stuty. The median follow up time was 14 months. 22 patients had recurrent disease only, 16 patients had metastatic disease only, and 2 patients had both recu...
The synergy of concurrent PD-1 inhibitor treatment with chemoradiotherapy shows promise as a treatment strategy and an acceptable toxicity for the R/M HNSCC patients....
Immune checkpoint inhibitors (ICIs) have made an important contribution to the survival of patients with certain cancers. ICIs interrupt co-inhibitory signaling pathways mediated by programmed cell de...
Immune evasion is essential for carcinogenesis and cancer progression. Programmed death-ligand 1 (PD-L1), a critical immune checkpoint molecule, interacts with programmed death receptor-1 (PD-1) on im...
Programmed cell death 1 (PD-1), as a negative immune regulator, regulates the activation of T cells and maintains the immune system's homeostasis. Previous studies suggest that the effective immune re...
The PD-1 rs10204525 was genotyped in 810 COVID-19 patients and 164 healthy individuals as a control group using Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Moreover,...
Regarding disease severity and mortality, no significant differences were detected between study groups in alleles and genotypes frequency distribution under different inheritance models. We found tha...
Considering the lack of significant differences in PDCD-1 expression in different genotypes in the control group, lower expression of PDCD-1 in COVID-19 patients carrying the G allele suggests the imp...
Immunomodulatory antibody drugs that modulate the function of immune checkpoint molecules, such as programmed death receptor-1 (PD-1) and programmed cell death ligand 1 (PD-L1), have been established ...